(S)-(-)-Bay K 8644
L-type Ca2+-channel activator with positive inotropic, vasoconstrictive and behavioral effects in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 356.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.81 mL||14.03 mL||28.07 mL|
|5 mM||0.56 mL||2.81 mL||5.61 mL|
|10 mM||0.28 mL||1.4 mL||2.81 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Franckowiak et al (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur.J.Pharmacol. 114 223 PMID: 2412855
O'Neill and Bolger (1988) Enantiomer selectivity and the development of tolerance to the behavioral effects of the calcium channel activator BAY K 8644. Brain Res.Bull. 21 865 PMID: 2465070
Ravens and Schopper (1990) Opposite cardiac actions of the enantiomers of Bay K 8644 at different membrane potentials in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch.Pharmacol. 341 232 PMID: 1692975
If you know of a relevant reference for (S)-(-)-Bay K 8644, please let us know.
View Related Products by Product Action
Keywords: (S)-(-)-Bay K 8644, (S)-(-)-Bay K 8644 supplier, Ca2+-channel, activators, L-type, Calcium, CaV, Channels, L-Type, voltage-gated, voltage-dependent, Ca2+, (S)-(-)-BayK8644, Voltage-gated, 1546, Tocris Bioscience
4 Citations for (S)-(-)-Bay K 8644
Citations are publications that use Tocris products. Selected citations for (S)-(-)-Bay K 8644 include:
Wei et al (2017) Inhibition of late sodium current suppresses calcium-related ventricular arrhythmias by reducing the phosphorylation of CaMK-II and sodium channel expressions. Sci Rep 7 981 PMID: 28428622
Burtscher et al (2014) Spectrum of Cav1.4 dysfunction in congenital stationary night blindness type 2. Biochim Biophys Acta 1838 2053 PMID: 24796500
Landstrom et al (2011) Junctophilin-2 expression silencing causes cardiocyte hypertrophy and abnormal intracellular calcium-handling. Eneuro 4 214 PMID: 21216834
Chen et al (2011) Neuromuscular synaptic patterning requires the function of skeletal muscle dihydropyridine receptors. Nat Neurosci 14 570 PMID: 21441923
Do you know of a great paper that uses (S)-(-)-Bay K 8644 from Tocris? Please let us know.
Reviews for (S)-(-)-Bay K 8644
There are currently no reviews for this product. Be the first to review (S)-(-)-Bay K 8644 and earn rewards!
Have you used (S)-(-)-Bay K 8644?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.